These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 12520524)

  • 21. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF; Lie A; Ransjö M
    J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
    Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
    Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RANKL expression is related to the differentiation state of human osteoblasts.
    Atkins GJ; Kostakis P; Pan B; Farrugia A; Gronthos S; Evdokiou A; Harrison K; Findlay DM; Zannettino AC
    J Bone Miner Res; 2003 Jun; 18(6):1088-98. PubMed ID: 12817763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
    Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT
    Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of inhibitory action of eldecalcitol, an active vitamin D analog, on bone resorption in vivo.
    Takahashi N
    J Steroid Biochem Mol Biol; 2013 Jul; 136():171-4. PubMed ID: 23220095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts.
    Tanabe N; Maeno M; Suzuki N; Fujisaki K; Tanaka H; Ogiso B; Ito K
    Life Sci; 2005 Jun; 77(6):615-26. PubMed ID: 15921993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice.
    Sakai A; Mori T; Sakuma-Zenke M; Takeda T; Nakai K; Katae Y; Hirasawa H; Nakamura T
    J Bone Miner Metab; 2005; 23(1):8-14. PubMed ID: 15616888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The molecular mechanism of osteoclastic bone resorption and inhibitory drugs for bone resorption].
    Yamamoto Y; Noguchi T; Udagawa N
    Clin Calcium; 2005 Jul; 15(7):11-6. PubMed ID: 15995290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells.
    Ishizuka S; Kurihara N; Miura D; Takenouchi K; Cornish J; Cundy T; Reddy SV; Roodman GD
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):331-4. PubMed ID: 15225795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
    J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating rapid responses to 1,25-dihydroxyvitamin D3 with transcriptional changes in osteoblasts: Ca2+ regulated pathways to the nucleus.
    Farach-Carson MC; Bergh JJ; Xu Y
    Steroids; 2004 Aug; 69(8-9):543-7. PubMed ID: 15288767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
    Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
    J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.